🔬 This service aims to meet the growing demand in cell-based therapies and regenerative medicine.
📈 CEO Irma Börcsök highlighted the service’s importance for clinical applications.
🧪 The company will showcase its GMP cell culture media at the ESGCT Congress in Seville from October 7–10.
Introduction:
PromoCell, a Heidelberg-based company, has announced its adoption of Good Manufacturing Practice (GMP) standards in response to the growing demand for advanced cell culture media tailored for clinical applications, especially in the realm of regenerative medicine and cell-based therapy.
- PromoCell is now offering custom GMP-grade cell culture media services, designed to accommodate the needs of the clinical and manufacturing sectors within the cell-based therapy industry.
- The company’s CEO, Irma Börcsök, highlighted the increasing demand for sophisticated cell culture media, which prompted the introduction of their GMP cell culture medium service portfolio.
- Dr. Lucía Cespón, the head of PromoCell’s GMP business unit, emphasized that their services and products are tailored to meet the precise needs of modern translational research.
- The new offerings include guidance throughout the entire research-to-commercialization process, ensuring compliance and precision in product development.
- PromoCell is set to exhibit its new services at the 32nd ESGCT Congress in Seville, Spain, from October 7–10, signaling its commitment to engage with the life science community.
Conclusion:
PromoCell’s move to adopt GMP standards marks a significant step in enhancing the quality and reliability of cell culture media for therapeutic applications. By offering tailored services and products, the company aims to facilitate advancements in the field of regenerative medicine and bolster the efficacy of cell-based therapies. Their participation in prominent industry congresses further illustrates their dedication to innovation and collaboration within the life sciences sector.
